Pradžia › Skrandžio vėžys › Utah
Skrandžio vėžys klinikiniai tyrimai Utah
14 tyrimai dėl Skrandžio vėžys ieško dalyvių vietose Utah.
Miestai Utah
Oficialus tyrimo tekstas (anglų kalba)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Intermountain Health, Salt Lake City
Renkami dalyviai1 fazė
Amžius 19 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06586957Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT05267626A Phase 1/1b Study of IAM1363 in HER2 Cancers
- START Mountain Region, West Valley City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT06253871A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- START Mountain Region, West Valley City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT07070232A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-11 · NCT06242470A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Utah Cancer Specialists, Salt Lake City
- University of Utah Health Huntsman Cancer Hospital, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-29 · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-22 · NCT05208762A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- START Mountain Region, Salt Lake City
- South Texas Accelerated Research Therapeutics Mountain Region, West Valley City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-22 · NCT06131840A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- START Mountain Region, LLC., West Valley City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-15 · NCT06657144Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-23 · NCT05005403Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-10 · NCT07517198Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-30 · NCT05297734A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- START Center for Cancer Care - Mountain Region, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-27 · NCT06395519SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.